172 related articles for article (PubMed ID: 21339073)
1. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
Schutz FA; Je Y; Choueiri TK
Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
[TBL] [Abstract][Full Text] [Related]
2. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of dermatological toxicities associated with sorafenib.
Zhang L; Zhou Q; Ma L; Wu Z; Wang Y
Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035
[TBL] [Abstract][Full Text] [Related]
4. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
Schutz FA; Jardim DL; Je Y; Choueiri TK
Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
[TBL] [Abstract][Full Text] [Related]
5. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
[TBL] [Abstract][Full Text] [Related]
7. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Zhou JX; Feng LJ; Zhang X
Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.
Zhao B; Zhao H
Oncotarget; 2017 Nov; 8(55):93813-93824. PubMed ID: 29212191
[TBL] [Abstract][Full Text] [Related]
9. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Crit Rev Oncol Hematol; 2013 Oct; 88(1):30-41. PubMed ID: 23830806
[TBL] [Abstract][Full Text] [Related]
10. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
Sher A; Wu S
Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
[TBL] [Abstract][Full Text] [Related]
12. Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.
Abdel-Rahman O; ElHalawani H
Future Oncol; 2015; 11(21):2949-61. PubMed ID: 26422782
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
14. Congestive heart failure risk in patients with breast cancer treated with bevacizumab.
Choueiri TK; Mayer EL; Je Y; Rosenberg JE; Nguyen PL; Azzi GR; Bellmunt J; Burstein HJ; Schutz FA
J Clin Oncol; 2011 Feb; 29(6):632-8. PubMed ID: 21205755
[TBL] [Abstract][Full Text] [Related]
15. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
Shameem R; Hamid MS; Wu S
Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
Pinto L; Liu Z; Doan Q; Bernal M; Dubois R; Lyman G
Curr Med Res Opin; 2007 Sep; 23(9):2283-95. PubMed ID: 17697451
[TBL] [Abstract][Full Text] [Related]
17. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
[TBL] [Abstract][Full Text] [Related]
18. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis.
Teo YL; Ho HK; Chan A
Cancer Treat Rev; 2013 Apr; 39(2):199-206. PubMed ID: 23099278
[TBL] [Abstract][Full Text] [Related]
19. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]